Prolyl-peptidyl isomerase, Pin1, phosphorylation is compromised in association with the expression of the HFE polymorphic allele, H63D  by Hall, Eric C. et al.
Biochimica et Biophysica Acta 1802 (2010) 389–395
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbad isProlyl-peptidyl isomerase, Pin1, phosphorylation is compromised in association with
the expression of the HFE polymorphic allele, H63D
Eric C. Hall II a, Sang Y. Lee a, Zachary Simmons b, Elizabeth B. Neely a, Wint Nandar a, James R. Connor a,⁎
a George M. Leader Family Laboratory, Department of Neurosurgery, Pennsylvania State University College of Medicine/Milton S. Hershey Medical Center, Hershey, PA 17033, USA
b Department of Neurology, Pennsylvania State University College of Medicine/Milton S. Hershey Medical Center, Hershey, PA 17033, USA⁎ Corresponding author. Department of Neurosurgery
University College of Medicine, 500 University Drive (H1
USA. Tel.: +1 717 531 4541; fax: +1 717 531 0091.
E-mail address: jconnor@psu.edu (J.R. Connor).
0925-4439/$ – see front matter. Published by Elsevier
doi:10.1016/j.bbadis.2010.01.004a b s t r a c ta r t i c l e i n f oArticle history:
Received 15 August 2009
Received in revised form 9 December 2009
Accepted 5 January 2010
Available online 12 January 2010
Keywords:
Pin1
Iron
HFE
Oxidative stress
Phosphorylation
Neurodegenerative disease
Transgenic miceThere is substantial interest in HFE gene variants as putative risk factors in neurodegenerative diseases such
as Alzheimer disease (AD). Previous studies in cell models have shown the H63D HFE variant to result in
increased cellular iron, oxidative stress, glutamate dyshomeostasis, and an increase in tau phosphorylation;
all processes thought to contribute to AD pathology. Pin1 is a prolyl-peptidyl cis/trans isomerase that can
regulate the dephosphorylation of the amyloid and tau proteins. Hyperphosphorylation of these later
proteins is implicated in the pathogenesis of AD and Pin1 levels are reportedly decreased in AD brains.
Because of the relationship between Pin1 loss of function by oxidative stress and the increase in oxidative
stress in cells with the H63D polymorphism it was logical to interrogate a relationship between Pin1 and HFE
status. To test our hypothesis that H63D HFE would be associated with less Pin1 activity, we utilized stably
transfected human neuroblastoma SH-SY5Y cell lines expressing the different HFE polymorphisms. Under
resting conditions, total Pin1 levels were unchanged between the wild type and H63D HFE cells, yet there
was a signiﬁcant increase in phosphorylation of Pin1 at its serine 16 residue suggesting a loss of Pin1 activity
in H63D variant cells. To evaluate whether cellular iron status could inﬂuence Pin1, we treated the WT HFE
cells with exogenous iron and found that Pin1 phosphorylation increased with increasing levels of iron. Iron
exposure to H63D variant cells did not impact Pin1 phosphorylation beyond that already seen suggesting a
ceiling effect. Because HFE H63D cells have been shown to have more oxidative stress, the cells were treated
with the antioxidant Trolox which resulted in a decrease in Pin1 phosphorylation in H63D cells with no
change in WT HFE cells. In a mouse model carrying the mouse equivalent of the H63D allele, there was an
increase in the phosphorylation status of Pin1 providing in vivo evidence for our ﬁndings in the cell culture
model. Thus, we have shown another cellular mechanism that HFE polymorphisms inﬂuence; further
supporting their role as neurodegenerative disease modiﬁers., H110, The Pennsylvania State
10), Hershey, PA 17033-0850,
B.V.Published by Elsevier B.V.1. Introduction
Alzheimer disease (AD) is a neurodegenerative disease that results
in cognitive deﬁciencies along with neuropathological changes
including accumulation of amyloid-beta (Aβ) plaques and neuroﬁ-
brillary tangles (NFT) [1–3]. Numerous studies have discovered that
biometals such as iron, copper, and zinc can directly impact AD
pathological markers [4–6]. Iron has been shown to directly regulate
amyloid precursor protein (APP) synthesis via an iron responsive
element in the 5′ UTR of APP mRNA [7]. Furthermore, iron and other
metals have been found in neuritic plaques and also inﬂuence
amyloid-beta (Aβ) aggregation [5,8–10]. The aggregation of tau
protein leading to NFT pathology is also impacted by iron [11,12]. Itis clear from these data thatmetal homeostasis in the brain is essential
for healthy brain aging and that identiﬁcation of genetic and
environmental factors that may disrupt the biometal homeostasis is
critical to identifying pathogenic mechanisms leading to neurode-
generative processes.
One such factor that combines gene and environment interaction is
HFE. The gene is located on chromosome6 andhas been investigated in
numerous genetics studies as a possible risk factor for developing or
modifying AD onset [13]. HFE protein is a major histocompatibility
class-1 like molecule that is reported to be involved in iron regulation
[14] and innate immunity [15,16]. One of the reported functions of HFE
protein is to complex with transferrin receptor (TfR) at the cell
membrane to decrease TfR afﬁnity for iron uptake [14]. When the
H63D HFE variant is expressed, the ability to limit iron uptake is lost,
resulting in increased cellular iron [14,17]. The elevated cellular iron
levels associatedwith theH63D can lead to oxidative stress [17,18] and
exacerbate the inﬂammatory response of macrophages [19]. Recently,
we have reported that cells carrying the H63D HFE have alterations in
glutamate homeostasis and tau phosphorylation [20,21]. These
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relevant to AD pathogenesis mechanisms that involve iron, oxidative
stress, and neuroinﬂammation.
The prolyl-peptidyl isomerase Pin1 can affect numerous cellular
mechanisms, such as protein localization, protein interactions, protein
dephosphorylation, transcription activity, enzymatic activity, protein
stability, and cell cycle regulation [22–24]. Of speciﬁc interest to AD,
Pin1 can regulate the phosphorylation of APP and tau at the threonine
668 and threonine 231 residues, respectively [25–28]. A deﬁciency in
Pin1 expression and/or activity appears to lead to the accumulation of
Aβ fragments and NFT formation suggesting that this enzyme could be
a key regulator of proteins involved in AD pathology [26,28,29].
Moreover, a study investigating mild cognitively impaired (MCI)
patients found Pin1 to be oxidatively modiﬁed and suggested that this
change could impact progression to develop AD [30]. Given the
interest in and potential for H63D variants of HFE to increase the risk
of AD [13], we examined the impact of H63D on Pin1 in a cell line and
newly developed animalmodel. Speciﬁcally, we hypothesized that the
presence of H63D HFE would be associated with decreased Pin1
activity.
2. Materials and methods
2.1. Chemicals and antibodies
Cell culture reagents including DMEM/F12, DMEM, pen/strep/
glutamine and Geneticin were purchased from Invitrogen (Carlsbad,
CA, USA). Fetal bovine serum was purchased from Gemini Bio-
Products (West Sacramento, CA, USA). DC protein assay was obtained
from Bio-Rad (Hercules, CA, USA). A rabbit polyclonal Pin1 antibody
was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
A rabbit polyclonal Pin1 (serine 16) antibody was purchased from Cell
Signaling Technology (Beverly, MA, USA).
2.2. Cell culture
Human neuroblastoma SH-SY5Y cell lines were obtained from
American Type Culture Collection (Manassas, VA, USA). Human
neuroblastoma SH-SY5Y cells were stably transfected to express
wild type and H63D HFE forms as previously reported along with a
vector alone control [31].We have previously reported that these cells
were chosen because endogenous expression of HFE could not be
detected. The transfected cells were maintained in DMEM/F12 media
supplemented with 10% FBS, 1% antibiotics (pen–strep–glutamine),
1× nonessential amino acids, and 1.8 g/L sodium bicarbonate. Cells
were differentiated with 10 µM all-trans retinoic acid (Sigma-Aldrich,
St. Louis, MO, USA) over six days [32]. To evaluate cellular iron effects,
cells were treated with ferric ammonium citrate (FAC) or desferriox-
amine (DFO) over 48 h (Sigma-Aldrich, St. Louis, MO, USA) [17].
2.3. Cell lysate preparation
Cells were lysed with RIPA buffer supplemented with 1% Triton X-
100 and protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO).
Phosphatase inhibitor (Sigma-Aldrich, St. Louis, MO) was included in
cell lysis buffer for phosphorylation protein detection. Cell extracts
were spun at 8000 ×g for 10 min. Total protein levels were
determined by Bio-Rad DC protein assay.
2.4. Enzyme-linked immunoabsorbant assay (ELISA)
The phosphorylation of APP at threonine 668 was determined
using a DuoSet IC ELISA assay (R & D Systems, Minneapolis, MN, USA).
An immobilized capture antibody formultiple APP isoforms that binds
phosphorylated and unphosphorylated protein was used to coat the
wells of a 96 well microplate overnight. Phosphorylated APPthreonine 668 protein standards were added to achieve a standard
curve to determine the speciﬁc amount of phosphorylated APP in
unknown HFE cell samples. A biotinylated detection antibody
recognizing APP threonine 668 was used to detect phosphorylated
APP using standard streptavidin-HRP. The ELISA assay plates were
read at 450 nm and 540 nm to correct for optical imperfections. All
solutions used throughout were provided or prepared according to
the manufacturer's recommendations. This ELISA experiment was
performed using samples in triplicate per genotype at two dilution
concentrations along with the known standards for the phosphory-
lated APP threonine 668 proteins, resulting in a total of six samples for
analysis.
A monoclonal antibody speciﬁc for human tau phosphorylated
residue threonine 231 was coated onto the wells of the microtiter
strips provided (Invitrogen, Carlsbad, CA, USA). Standards of known
phosphorylated tau threonine 231 proteins were processed to achieve
a standard curve to determine the speciﬁc amount of phosphorylated
protein in the unknown HFE cell samples. The ELISA assay plate was
read at 450 nm. This ELISA experiment was performed using samples
in triplicate per genotype at two dilution concentrations along with
the known standards for the phosphorylated tau threonine 231
proteins, resulting in a total of six samples for analysis.
2.5. Western blot
Cells lysates were obtained as described above. Twenty-ﬁve to
forty µg total protein was equally separated by electrophoresis in a 4–
20% 12-well Criterion gel (Bio-Rad, Hercules, CA). Protein was then
transferred to a nitrocellulose membrane and blocked for 1 h at room
temperature in TBS-T with 5% nonfat milk or 1.5% BSA (phosphory-
lated protein detection). Membranes were probed with primary
antibodies in TBS-T with 5% nonfat milk overnight at 4 °C. The
membranes were incubated with antibodies speciﬁc for total Pin1
(1:1000), Pin1 serine-16 (1:500), and β-actin (1:5000). HRP-
conjugated secondary antibodies were added in 5% nonfat milk for
1 h at room temperature. Protein signals were obtained by chemilu-
minescence and visualized by CCD camera. All western blot experi-
ments were repeated at least twice with a minimum of four different
cultures per genotype per experiment, resulting in a total of eight
samples for analysis. The bands on the western blot were quantiﬁed
by densitometry using Fuji MultiGauge analysis software.
2.6. Mouse model
H67D knock-in mice of mixed C57BL6×129SvEv genetic back-
ground were developed similar to the H67Dmouse model of Tomatsu
et al. [33]. Homozygote H67D and wild type mice were generated by
intercrossing H67D heterozygote mice. Genotype was conﬁrmed by
PCR analysis. All of thesemiceweremaintained under normal housing
conditions in accordancewith Penn State University's IUCAC policy for
animal use, which is in agreement with the NIH Guide for the Care and
Use of Laboratory Animals. Male and female mice at 6 months of age
were examined. Protein for biochemical analysis was obtained from
mice brain removal after the mice were anesthetized.
2.7. Statistical analysis
The Student's t-test was used for analyzing HFE variant compar-
isons when one variable was being determined. Experimental data
where samples were treated with various agents (i.e. iron or
desferrioxamine) and compared with controls were analyzed by
one-way analysis of variance. Differences among the means were
considered statistically signiﬁcant when the p value was b0.05. If
overall pb0.05, Tukey's multiple comparison post-hoc analysis was
performed. Data are presented as the mean±S.E.; GraphPad Prism
software (version 4.0) was utilized to perform the statistical analysis.
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3.1. HFE effects on Pin1 levels and phosphorylation
The ﬁrst study was designed to examine total Pin1 protein
expression as a function of genotype. No signiﬁcant differences
were found (Fig. 1). The function of Pin1 can be altered by its
phosphorylation state at its serine 16 residue, which is located at the
center of the phosphorylated serine/threonine-proline binding
pocket [34,35]. Therefore we used the analysis of phosphorylated
Pin1 as a surrogate marker for Pin1 activity. The phosphorylation of
Pin1 at its serine 16 residue was signiﬁcantly increased (30%) in cells
expressing the H63D variant (pb0.01) compared to the vector and
wild type HFE cells (Fig. 1). These data would suggest that there is
approximately a 30% decrease in the activity of Pin1 in H63D cells.
3.2. The impact of cellular iron on Pin1
Because HFE is involved in regulating cellular iron status and we
have shown that there is more iron in the labile iron pool in cells
carrying the H63D variant, the second study was to determine if iron
could impact Pin1 phosphorylation status. Upon, treating the wild
type HFE cells with ferric ammonium citrate (FAC), total Pin1 protein
expressionwas unaffected (Fig. 2A) but the phosphorylation of Pin1 at
serine 16 increased in a dose-dependent manner (Fig. 2B). However,
any differences in Pin1 phosphorylation in the H63D carrying cells
treated with FAC did not reach statistical signiﬁcance at pb0.05 at the
same concentrations of iron provided to WT cells (Fig. 2B).
3.3. Removal of iron affects Pin1 phosphorylation in HFE H63D cells
To continue to evaluate the sensitivity of Pin1 phosphorylation to
iron availability, WT and H63D cells were treated with the iron
chelator desferrioxamine (DFO). Pin1 phosphorylation was unaffect-
ed in the WT HFE cells by iron chelation but was decreased with
10 µM DFO treatment (pb0.01) in the H63D HFE cell lines (Fig. 3).
3.4. Antioxidant affects Pin1 phosphorylation in HFE H63D cells
Increased cellular iron can result in oxidative stress. There is
evidence of oxidative stress impacting the cellular activity of Pin1Fig. 1. Pin1 levels and phosphorylation. Expression of total Pin1 protein and Pin1 activity det
transfected SH-SY5Y cell line by western blot. The data show that there were no signiﬁcant d
in H63D expressing cells (pb0.01) compared to cells containing wild type HFE. Experiments w
western blot images are shownwith graphs displaying differences in expression determined
by Tukey's post-hoc analysis. Data are represented as mean±S.E. The symbol ** (pb0.01) i[30,36,37] and we have shown increased indices of oxidative stress in
H63D expressing cells [17]. Therefore, we treated the cells expressing
the HFE variants with Trolox, a vitamin E analog to decrease cellular
oxidative stress. Pin1 phosphorylation decreased approximately 20%
with Trolox treatment in H63D cells (p=0.0257), but was unchanged
in the control WT expressing cells treated with Trolox (Fig. 4).
3.5. HFE and Pin1 Alzheimer's disease protein substrates
Pin1 has been shown to regulate the phosphorylation of AD related
proteins [25,26,28]. Therefore, APP phosphorylation at its threonine
668 residue was measured in HFE cells by enzyme-linked immu-
noabsorbant assay (ELISA). APP phosphorylation was increased in
vector cells by approximately 65% (pb0.01) compared to cells
expressing wild type HFE (Fig. 4). Cells expressing the H63D variant
had 50% less APP threonine 668 phosphorylation (pb0.05) with
respect to WT HFE cells (Fig. 5). Tau threonine 231 phosphorylation
was evaluated by ELISA and was decreased in vector cells (pb0.01) by
42% and H63D expressing cells (pb0.05) by 33% compared to cells
expressing WT HFE (Fig. 5).
3.6. Pin1 levels and phosphorylation in an H67D transgenic mouse model
To further assess the impact of H63D HFE on Pin1, we examined
Pin1 levels and phosphorylation in vivo. We evaluated the H67D HFE
mice, which express an HFE point mutation H67D that is homologous
to human H63D [33]. Total Pin1 levels were not changed among the
mice expressing an H67D allele compared to wild type mice (Fig. 6).
Pin1 phosphorylation levels at its serine 16 residue were signiﬁcantly
increased in H67D homozygous mice (pb0.05) and H67D heterozy-
gous mice (pb0.05) compared to wild type mice, respectively (Fig. 6).
These data further support our cell culture ﬁndings demonstrated in
this manuscript.
4. Discussion
The H63D variant of HFE gene is under examination as a risk factor
for neurodegenerative diseases [13]. We have established a cell model
in which to directly examine the impact of HFE polymorphisms on an
otherwise homogenous genetic background in a controlled culture
condition. The controlled conditions are essential to understandingermined by its serine 16 phosphorylation was measured in an HFE polymorphism stably
ifferences in total Pin1 protein levels. Pin1 phosphorylation was signiﬁcantly increased
ere performed with aminimum of four different cultures per genotype. Representative
by densitometric analysis. One-way ANOVAwas performed to analyze the data followed
ndicates a signiﬁcant difference from wild type HFE.
Fig. 2. Cellular iron effects on Pin1 expression and phosphorylation. We added increasing amounts of ferrous ammonium citrate (FAC) to cells expressing wild type and H63D HFE.
Total Pin1 protein levels were not changed with iron treatments (A). Pin1 activity decreased with increasing amounts of iron in a dose-dependent fashion in wild type cells (10 µM,
pb0.01) and (30 µM, pb0.001) as indicated by an increase in Pin1 serine 16 phosphorylation (B). Additionally, we further challenged the H63D cells by treating themwith iron in the
form of FAC. H63D expressing cells did not achieve a statistical signiﬁcant increase in Pin1 serine 16 phosphorylation with iron treatments (B). Experiments were performed with a
minimum of four different cultures per genotype. Representative western blot images are shown with graphs displaying differences in expression determined by densitometric
analysis. One-way ANOVA was performed to analyze the data followed by Tukey's post-hoc analysis. Data are represented as mean±S.E. The symbols ** (pb0.01) and *** (pb0.001)
indicate signiﬁcance from the respective non-treated group.
392 E.C. Hall II et al. / Biochimica et Biophysica Acta 1802 (2010) 389–395the contribution of HFE gene variants to neurodegenerative disease
because of the likelihood of gene/environment interaction given the
availability of iron in the environment. Our working hypothesis for
H63D HFE gene variants and neurodegenerative disorders is that the
H63D allelic variants does not in itself cause disease but creates a
permissive or enabling cellular milieu for pathogenic agents. We have
previously reported that expression of the H63D HFE variant in stably
transfected SH-SY5Y cells results in increased cellular stress [17],
altered glutamate homeostasis [21], and increased tau phosphoryla-
tion [20]. Oxidative stress and glutamate excitotoxicity are indirectly
thought to contribute to neurodegeneration in AD whereas tauphosphorylation is more directly implicated as part of the pathogen-
esis of AD [38,39]. In this study, we extend these observations to show
that Pin1, an enzyme responsible for regulating phosphorylation of
amyloid and tau, is altered in cells expressing H63D HFE and in a
mouse model expressing H67D the human equivalent of the H63D
gene variant.
Total Pin1 expression levels were found to be unchanged between
the HFE polymorphisms and the transfection vector control. Pin1
phosphorylation at serine 16 was signiﬁcantly increased in cells that
expressed the H63D variant compared to wild type HFE cells implying
that Pin1 activity is decreased. We expanded the cell culture results
Fig. 3. Iron chelation and Pin1 phosphorylation. Increasing amounts of the iron chelator desferrioxamine (DFO) were added to cells expressing wild type and H63D HFE. Pin1 activity
was measured by western blot via phosphorylation of Pin1 at serine 16. Pin1 activity was not altered whenWT cells were treated with DFO. DFO treatment of H63D cells resulted in
an increase in Pin1 activity as indicated by a decrease in phosphorylation of Pin1 at serine 16. At 5 µM DFO, there was not a signiﬁcant difference compared to the non-treated H63D
group. Upon treating the H63D cells with 10 µM DFO, there was a signiﬁcant decrease (pb0.01) in Pin1 phosphorylation. Experiments were performed with a minimum of four
different cultures per genotype. Representative western blot images are shown with graphs displaying differences in expression determined by densitometric analysis. One-way
ANOVA was performed to analyze the data followed by Tukey's post-hoc analysis. Data are represented as mean±S.E. The symbol ** (pb0.01) indicate signiﬁcance from the
respective non-treated group.
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expressing the equivalent of the H63D HFE polymorphism. The data
from the H67D HFE mice studies showed similar results to the cell
model as total Pin1 levels were unchanged and Pin1 phosphorylation
levels increased with expression of an H67D allele.
To determine the cause of the increased phosphorylation of Pin1,
we examined the cellular iron status and oxidative stress because of
the previous literature indicating a relationship between oxidative
stress and H63D and the vulnerability of Pin1 to oxidative stress.
H63D HFE cells have more labile iron in the cytosol [17,19] than WTFig. 4. Trolox treatment and Pin1 phosphorylation. HFE polymorphism stably transfected SH
Trolox, a water-soluble vitamin E analog to assess the effect of oxidative stress on Pin1 activ
was an increase in Pin1 activity upon treating H63D cells with Trolox as evidenced by a decr
analyze the data; data are represented as mean±S.E. The symbol * (pb0.05) indicates a sigHFE cells. To determine if the higher iron content was potentially
related to the increased phosphorylation of Pin1, we treated the wt
cells with increasing amounts of iron which resulted in a dose-
dependent increase in phosphorylation of Pin1. We also challenged
the H63D HFE cells with more iron to determine if we could further
increase the phosphorylation of Pin1 but increasing amounts of iron
did not signiﬁcantly increase Pin1 phosphorylation suggesting a
ceiling effect. Chelating iron resulted in a reduction of Pin1
phosphorylation in the H63D HFE cells but not in the WT HFE
expressing cells. The cellular iron effects on Pin1 based on HFE-SY5Y cells expressing wild type and H63D variant were treated for 72 h with 200 μM
ity determined by western blot. Trolox treatment had no effect on WT HFE cells. There
ease in Pin1 serine 16 phosphorylation (p=0.0257). Student's t-test was performed to
niﬁcant difference from baseline H63D HFE.
Fig. 5. HFE effects on Alzheimer disease Pin1 substrates. The phosphorylation of amyloid and tau proteins at threonine 668 (t668) and threonine 231 (t231), respectively, has been
shown to be impacted by Pin1 activity. APP t668 protein levels were increased in vector cells (pb0.01) compared to wild type HFE cells determined by an ELISA assay. APP t668 levels
were decreased in H63D expressing cells (pb0.05) compared to WT HFE cells. Tau t231 protein levels were decreased in vector (pb0.01) and H63D cells (pb0.01) with respect to
cells expressing wild type HFE. The vector only cells are a control for transfection, but because the cells do not express detectable HFE [17] they are not the appropriate comparison
for the effect of the H63D allelic variant. Experiments were performed with a minimum of four different cultures per genotype. One-way ANOVA was performed to analyze the data
followed by Tukey's post-hoc analysis. Data are represented as mean±S.E. The symbols * (pb0.05) and ** (pb0.01) indicate a signiﬁcant difference from wild type HFE.
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cells that is available to alter phosphorylation status of Pin1 and can
be mimicked by elevating the iron status in the WT HFE cells.
The iron effect on Pin1 could be indirect due to oxidative stress
through the Fenton reaction [4,40]. Higher indices of oxidative stress
associated with the H63D HFE allele have been demonstrated in our
cell line and human patient data [17,18,41]. To determine the role of
oxidative stress, we treated the HFE polymorphism carrying cells with
the antioxidant Trolox, a vitamin E analog. In the WT HFE cells, there
was not a change in Pin1 phosphorylation following Trolox exposure
but Trolox treatment in the H63D cells resulted in a decrease in Pin1
serine 16 phosphorylation. These data suggest that Pin1 activity, under
resting conditions in the presence of H63DHFE is affected by oxidative
stress. Our data are consistent with the ﬁndings of other groups
[30,36,37] showing that Pin1 can be impacted by oxidative stress.
The increase in Pin1 phosphorylation at serine 16 in association
with the H63D HFE mutation could lead to cellular changes associatedFig. 6. Pin1 levels and phosphorylation in an H67D transgenic mousemodel. Total Pin1 protei
mouse H67D point mutation is homologous to the human H63D polymorphism. There were
(−/−), heterozygous H67D (+/−), and wild type (+/+) HFE mice. Pin1 phosphorylation
(pb0.05) and in H67D heterozygous mice (pb0.05) compared to wild type mice, respective
Data are represented as mean±S.E. The symbol * (pb0.05) indicates a signiﬁcant differenc
graphs displaying differences in expression determined by densitometric analysis. One-way
are represented as mean±S.E. The symbol * (pb0.05) indicates a signiﬁcant difference fromwith AD, speciﬁcally the inability to dephosphorylate APP and tau
proteins [25,27,42]. Pin1 is an intracellular regulator of amyloid and
tau protein phosphorylation at the APP threonine 668 and tau
threonine 231 amino acid residues, which appear to be important to
the pathological generation of Aβ plaques and tangles [26,28,29]. To
evaluate the consequence of altered Pin1 function in H63D variant
cells, we determined the phosphorylation of APP threonine 668 and
tau threonine 231 levels in HFE expressing cells. Surprisingly, we
found a signiﬁcant decrease in APP phosphorylation in H63D cells
compared to cells expressing wild type HFE. Furthermore, a signiﬁcant
reduction at the tau threonine 231 residue occurred in the H63D
expressing cells, consistent with previous ﬁndings [20]. These data are
not consistent with the reduction in Pin1 activity in H63D variant cells.
The apparent inconsistency may be explained by our previous report
of a reduction in cyclin-dependent kinase 5 (cdk-5) expression and
activity in H63D polymorphism expressing cells [20]. Cdk-5 has been
shown to regulate the phosphorylation of these proteins at then and phosphorylation levels were determined in 6 month old H67D knock-inmice. The
no signiﬁcant differences in total Pin1 protein levels among homozygous H67D/H67D
levels at its serine 16 residue were signiﬁcantly increased in H67D homozygous mice
ly. Experiments were performed with a minimum of three mice per genotype (n=3).
e from the WT (+/+) HFE mice. Representative immunoblot images are shown with
ANOVA was performed to analyze the data followed by Tukey's post-hoc analysis. Data
wild type HFE mice.
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respectively [38,43–46]. Furthermore, the indirect evidence of
decreased Pin1 activity data in the H63D cells are consistent with
the increased GSK-3β activity associated with expressing the H63D
variant [20]. Min et al. showed that lithium inhibition of GSK-3β
resulted in an increase in Pin1 activation suggesting that regulating
GSK-3βmay affect Pin1's ability to dephosphorylate its substrates such
as tau [47]. These data, in association with our ﬁndings that Trolox
effects on Pin1 in this study are affected by H63D HFE expression are
compelling evidence that theHFE polymorphism should be considered
when evaluating treatment strategies in neurodegenerative diseases.
We conclude that the discovery of HFE, implicated as a putative risk
factor for neurodegenerative disease such as AD can impact Pin1 is
clinically meaningful and given the abundance of iron in the diet and
environment, further investigation is warranted into the gene–
environment interaction between HFE polymorphisms and iron.References
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